drugset / Trial / NCT05106517

Denosumab vs Zoledronic Acid and Osteoporotic Compression Fracture

NCT05106517

Phase 2/3 Unknown 122 enrolled Shenzhen People's Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Bone mineral density and function at 1 year after screw fixation with denosumab vs zoledronic acid for osteoporotic vertebral compression fractures: a parallel double-blind randomized controlled clinical trial

Timeline

Start
2021-09-08
Primary completion
2023-03-05
Completion
2023-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Denosumab Monoclonal antibody 60 mg Subcutaneous
Subject Zoledronic acid Other / unclassified Intravenous

Indications

No indication recorded.